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The intestinal milieu harbours the gut microbiota, consisting of a complex
community of bacteria, archaea, fungi, viruses and protozoans that bring
to the host organism an endowment of cells and genes more numerous
than its own. In the last 10 years, mounting evidence has highlighted the
prominent influence of the gut mutualistic bacterial communities on human
health. Microbial colonization occurs alongside with immune system devel-
opment and plays a role in intestinal physiology. The community of the
gut microbiota does not undergo significant fluctuations throughout adult
life. However, bacterial infections, antibiotic treatment, lifestyle, surgery
and diet might profoundly affect it. Gut microbiota dysbiosis, defined as
marked alterations in the amount and function of the intestinal microor-
ganisms, is correlated with the aetiology of chronic noncommunicable dis-
eases, ranging from cardiovascular, neurologic, respiratory and metabolic
illnesses to cancer. In this review, we focus on the interplay among gut
microbiota, diet and host to provide a perspective on the role of micro-
biota and their unique metabolites in the pathogenesis and/or progression
of various human disorders. We discuss interventions based on microbiome
studies, that is faecal microbiota transplantation, probiotics and prebiotics,
to introduce the concept that correcting gut dysbiosis can ameliorate dis-
ease symptoms, thus offering a new approach towards disease treatment.
Introduction
Daily, our body is exposed to a wide variety of foods.
Similarly to drugs, these materials are recognized
as ‘not-self’ and may represent a potential source of
toxicity [1].
To assess adherence to dietary guidelines meant to
promote health and prevent chronic disease, the
Healthy Eating Index (HEI) was developed in the Uni-
ted States. The most updated version of the HEI
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focused on food quality, including healthy choices
such as whole grains, seafood and plant proteins [2].
What emerged from recent prospective studies is that
the majority of the population in the United States
achieved only an intermediate or poor HEI, as
reported in the National Health and Nutrition Exami-
nation Survey [3].
Bacteria, the main types of microorganisms, together
with archaea, fungi, viruses (especially bacteriophages)
and protozoans are found in the mammalian intestine
[4]. These latter groups of microorganisms likely mod-
ulate the activities of the host and may be as impor-
tant as bacteria [5,6]. By definition, the collective
microbial community present inside and on the surface
of the human body constitutes our microbiota,
whereas the term microbiome refers to the genes
expressed by the microbiota [7]. The stomach and
small intestine have a bacterial density of about 103–
105 organisms/g in mice. The ileum, which corresponds
to the distal portion of the small intestine, has a higher
bacterial density (108/g) and species diversity. The
highest density of colonization is found in the colon
(1010–1012/g), with a spectrum of at least 400 bacterial
species. In the lower intestine, anaerobes are predomi-
nant, particularly Bacteroides, Bifidobacteria, Fusobac-
teria and Peptostreptococci. On the other hand,
aerobes and facultative aerobes, including Enterobacte-
ria and Lactobacilli, are present at only moderate den-
sity [8]. The microbiome composition is unique to each
individual, rapidly developing throughout early child-
hood to become established in adulthood. Modifica-
tions in microbial composition depend on both genetic
and environmental factors including diet, geographical
location, toxin/carcinogen exposure and hormones [9].
This review focuses on the connections among gut
microbiota (mainly the bacterial fraction), diet and
human illnesses. Specifically, we discuss the role of gut
bacteria and diet in the pathophysiology of cardiovas-
cular disease (CVD), central nervous system (CNS)
syndromes and cancer.
The gut microbiota system
The intestinal microbial community that inhabits the
human gut counts more than 100 trillion microbial
cells (~ 4 9 1013), lives in a mutualistic relationship
with its host and is a key contributor to host metabo-
lism, for instance by producing vitamins and others
metabolites necessary to the host’s physiology. For this
reason, dramatic changes in the composition and func-
tion of intestinal microorganisms, defined as gut
microbiota dysbiosis, are associated with gastroenteric
disorders, as well as neurologic, respiratory, metabolic,
hepatic and CVD [10]. Bacteria also inhabit extrain-
testinal organs such as skin, oral and nasal cavities,
and vagina, but their number in these compartments
does not exceed 1012/g [11].
Shotgun metagenomics sequencing through random
sequencing of all genes established that the bacterial
microbiome of the human gut is dominated by Firmi-
cutes, Bacteroidetes, Actinobacteria, Proteobacteria and
Verrucomicrobia phyla. Firmicutes and Bacteroidetes
represent 90% of the gut microbiota [7]. Arumugam
et al. proposed that the gut microbiota is grouped into
three enterotypes or clusters, namely Bacteroides, Pre-
votella and Ruminocccus [12]. However, further studies
showed that discrete clustering methodologies could be
sensitive to sampling and selection bias, providing evi-
dence that enterotypes are fluid entities rather than
discrete community types [13]. Recently, Costea
et al.[14] concluded that, even though an appropriate
statistical description of the microbiome remains elu-
sive, the enterotype composition is still relevant in var-
ious clinical settings, ranging from direct disease
associations to personalized dietary interventions.
The intestine is colonized by microorganisms prena-
tally, reaching a steady state between 2 and 5 years of
age. Several studies have demonstrated that the foetus
lives in a nonsterile environment and the microbes that
colonize the foetus could influence both the pregnancy
outcome and later on the health status of the infant
[15,16]. Following birth, various microbes colonize the
human intestine, and factors like gestational age, mode
of delivery, diet (breastmilk vs. formula), sanitation
and antibiotic treatment are known to affect this pro-
cess [17]. In the preterm neonate, the microbiota have
reduced diversity with lower numbers of Bifidobac-
terium and Bacteroides and higher levels of Enterococ-
cus and Proteobacteria compared to full-term children.
Of note, high concentrations of Proteobacteria have
been recognized as a risk factor for the development
of neonatal-necrotizing enterocolitis (NEC) [18].
Maternal vaginal and faecal bacteria, including Lacto-
bacillus and Bifidobacterium, colonize vaginally deliv-
ered infants [19]. Enterobacteriaceae represent the main
group of microorganisms transferred from mother to
child through faeces [20]. Neonates born via C-section,
thus not directly exposed to maternal microorganisms,
are colonized by microbes coming from the skin and
the hospital environment. The main consequence is
that C-section delays Bacteroidetes colonization and
reduces microbiota diversity. However, as more recent
studies report conflicting results, it remains unclear
whether disruption of mother-to-infant transmission of
microbiota through C-section occurs and whether it
affects human physiology early on [21,22]. Besides,
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long-term follow-up trials based on larger cohorts,
high-resolution multi-omics analyses and detailed
immunological screening are necessary to unravel the
relationships between mode of delivery and health sta-
tus [23].
Infant feeding methods, namely breastmilk and for-
mula, dramatically shape the gut microbiota in early
life. Human milk contains proteins, fats, carbohydrates
(mainly oligosaccharides), immunoglobulins and endo-
cannabinoids. The milk oligosaccharides reach the
colon where are fermented, mainly by Bifidobacterium,
to produce short-chain fatty acids (SCFAs), mainly
acetic, propionic and butyric acids [17,24,25]. A direct
correlation between oligosaccharides present in the
human milk and number of Bifidobacterium has been
found, showing that these milk components act as pro-
biotics by selectively promoting the formation of Bifi-
dobacterium-rich microbiota [26]. Based on these data,
milk formula has been optimized by adding certain
types of oligosaccharides, making it possible for
infants to establish Bifidobacterium-rich microbiota
[27]. Breastmilk contains also immunoglobulins (IgA
and IgG), lysozyme, lactoferrin, immune-regulatory
cytokines (e.g. TGF-b and IL-10) and lymphocytes
expressing gut homing markers [28,29]. For this rea-
son, intestinal bacterial colonization dramatically influ-
ences the maturation and physiology of the immune
system in early life and affects adult’s health and dis-
ease, as pointed out by the loss of immune function in
germ-free mice [30]. Various studies have also demon-
strated that intestinal bacteria and their metabolites,
including SCFAs, play a key role in the proliferation
and differentiation of T and B cells [29,31,32].
A marked transformation in the gut microbial com-
munity occurs after weaning from the mother and the
introduction of solid foods, with an increase in the
number of butyrate producers, that is Bacteroides and
Clostridium species [33]. Antibiotics use significantly
impacts the evolution of the infant gut microbiota by
increasing Proteobacteria and lowering Actinobacteria
populations [34], decreasing the overall diversity and
selecting for drug-resistant bacteria. Moreover, some
epidemiological studies correlated the antibiotic con-
sumption in early life with the increased risk of allergic
disease (i.e. asthma, atopic dermatitis, eczema) and
type-1 diabetes later on in life [35].
Compared to infants, the gut microbiome of chil-
dren is characterized by a higher degree of stability
and a reduced interindividual variance. In childhood,
gut microbiota are influenced by geography and food
culture and differ between developed and developing
countries, as well as between industrialized and rural
areas [15]. For example, it has been reported that the
gut microbiota of children from Burkina Faso were
enriched of Bacteroides, while Enterobacteriaceae,
pathogenic intestinal microbes causing diarrhoea, were
significantly lower compared to Italian children [36]. A
meta-analysis of metagenomic datasets obtained from
faecal samples of healthy adults living in 13 different
industrialized regions, as well as two preagricultural
communities, indicated that the urbanization process
has significantly shaped the gut microbiota, thereby
potentially impacting the overall functionality of the
gut microbiome [37]. Besides, epidemiologic studies
have suggested that the incidence of autoimmune dis-
orders is increasing in industrialized countries poten-
tially reflecting environmental/dietary/microbial
population changes [38]. In adulthood, the gut micro-
biota community is to some extent stable. However, a
higher level of interindividual variability has been
observed in the gut microbiota composition of aged
people compared to younger adults [39]. Centenarians
had reduced concentrations of Bacteroides, Bifidobac-
terium and Enterobacteriaceae, while Clostridium spe-
cies concentrations were increased compared with
younger adults. A correlation between gut microbiota
composition, diet and institutional or community liv-
ing was also reported. It will be necessary to devise
new dietary intervention studies to fully understand
and elucidate the clinical relevance of these modifica-
tions. Specifically, it should be important to establish
if a controlled variation on the dietary habits of aged
individuals could positively impact their gut micro-
biota composition in a context of global ageing popu-
lation [40,41].
Diet
Changes in socio-economic status, cultural traditions,
population growth and employment impact dietary
habits worldwide. Finding ways to increase the pro-
duction and availability of healthy foods is a major
need, giving the exponential growth of the global pop-
ulation, whose size is predicted to expand to 9 billion
by 2050 [42,43]. Various studies have demonstrated
that the nutritional value of food is partially affected
by the composition of the individual’s gut microbiota,
and that food, in turn, moulds both the microbiota
and the microbiome [44,45]. In line with these data, we
have to keep in mind that also plant hormones (such
as abscisic acid, auxins and salicylates) and polyphe-
nols (such as curcumin, lignans and cinnamic acid) can
influence microbial richness, diversity and composition
[46,47]. Besides, abscisic acid, salicylates and curcumin
exert positive effects against chronic and degenerative
disease, including diabetes and cancer [48–50]. Finally,
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answering the question of how food processing by the
gut microbiota influences our immune system will give
us the whole picture of this complex network.
It is still unclear what defines a ‘healthy’ microbiota.
We know that 30–40% of the gut microbiota in the
adult can be modified during the lifetime, and diet is
one of the most powerful instruments to do so. For
example, the Bacteroides enterotype is found in indi-
viduals consuming fat and protein-rich diet, whereas
the Prevotella enterotype is often present in the gut
microbiota of persons eating a fibre’s rich diet. It has
been estimated that about 90–95% of dietary fats are
absorbed in the small intestine, which may explain
why fats dramatically impact the gut microbiota com-
position [51,52]. High-fat diets are indeed associated
with low SCFAs and low Bifidobacterium concentra-
tions [53]. Mice fed a palm oil-based diet show an
increase in the ratio of Firmicutes to Bacteroidetes, an
elevation in Clostridium species, and a reduction of
overall microbiota diversity [51]. Proteins are an inte-
gral part of a healthy diet, but it has been shown that
the relationship between protein intake and health fol-
lows a U-shaped curve [54,55]. Specifically, intakes
below the minimum are associated with undernutrition
states, and intakes above the tolerable limit are associ-
ated with overnutrition illnesses [56]. Clinical studies
indicate a linear correlation between the levels of pro-
tein intake and the long-term risk of kidney disease in
people with below normal kidney function, and a non-
linear relationship with long-term mortality risk
regardless of kidney dysfunction [56]. It has been
demonstrated that dietary proteins reaching the colon
(about 10%) act both as a substrate for proteolytic
bacteria and as a source of nitrogen for saccharolytic
species [57]. The products of protein and amino
acid breakdown are SCFAs, branched-chain fatty
acids (BCFAs; isobutyrate, isovalerate and 2-
methylbutyrate), phenol compounds (phenylpropi-
onate, phenylacetate, p-cresol, indole propionate and
indole acetate), amines, sulphides and ammonia
(Fig. 1). Microorganisms involved in deamination are
Clostridium, Bacteroides and Enterobacterium species
[58]. For example, the acetate-producing commensal
Bacteroides thetaiotaomicron and the Faecalibac-
terium prausnitzii induce goblet cell proliferation and
mucus production, both effects able to maintaining gut
homeostasis and epithelial integrity [59]. On the other
hand, depletion of acetate-producing Bifidobacteria in
mice increased susceptibility to infections and pro-
moted intestinal inflammation [54]. Moreover, proteins
are the source of L-carnitine and choline [60,61], which
can be fermented by bacteria to trimethylamine
(TMA) and subsequently oxidized to trimethylamine
N-oxide (TMAO) via flavin monooxygenase 3 (FMO3)
(Fig. 1) [62]. Metabolomic studies suggested that high
TMAO concentrations are positively correlated with
cardiovascular events such as death, myocardial infarc-
tion (MI) and stroke [63]. In line with these data, in
Apoe-deficient mice fed a TMAO-rich diet increased
macrophage foam cell formation and aortic atheroscle-
rotic plaque development was observed [28,64].
Besides, dietary L-carnitine and choline were similarly
associated with atherosclerosis worsening and reduc-
tion of reverse cholesterol transport in mouse models
with an intact gut microbiota [65–67]. Furthermore,
high L-carnitine and TMAO levels were correlated with
increased risk for MI or death in a clinical study with
a 3-year follow-up [68].
Dietary fibres are polysaccharides divided into resis-
tant starches and nonstarch polysaccharides, which are
not digested by human enzymes and are able to
enlarge the faecal mass and increase the motility of the
intestine [69,70]. The nonstarch polysaccharides
include cellulose (a substrate for SCFAs synthesis) and
Fig. 1. Microbial metabolite-driven
pathways. Intestinal bacteria convert dietary
nutrients to metabolites able to modulate
the immune system and alter risk of
developing atherosclerotic cardiovascular
disease and cognitive decline.
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noncellulose fibres, that is pectins, gums, glycosamino-
glycans, alginates, carrageenans, chitosans and
fucoidans. A significant reduction of the Rose-
buria/ eubacterium rectale group and of the faecal
levels of SCFAs has been correlated with the con-
sumption of a high-fibre’s diet (Fig. 1). Several trypto-
phan metabolites (e.g. indole-3-carbinol and indole
[3,2b] carbazole) and xenobiotics (e.g. 2,3,7,8-tetra-
chlorodibenzo-p-dioxin, TCDD) are ligands of the aryl
hydrocarbon receptor (AhR), which has been shown
to significantly influence host metabolism and immu-
nity [71]. Ahr-deficient mice display various immuno-
logical deficits, including a higher sensitivity to Listeria
monocytogenes or Citrobacter rodentium-induced infec-
tions [72,73]. Experimental studies have demonstrated
that IL-22 plays a key role in the protection against
this kind of infections by stimulating (a) the secretion
of antimicrobial peptides from epithelial cells, (b) the
production of mucins and (c) the proliferation of
intestinal goblet cells. Besides, microbiota-derived tryp-
tophan metabolites have the ability to modulate the
AhR-IL-22 axis, thus impacting mucosal immune
homeostasis in the gut [74]. Importantly, high expres-
sion of IL-22 has been detected in tumour tissues and
it has been correlated with cancer progression and
poorer patient survival in pancreatic ductal adenocar-
cinoma [75]. Therefore, dietary-induced modifications
of host metabolomics and the presence of environmen-
tal contaminants may alter physiological homeostasis,
impacting host fitness and leading to inflammatory
responses.
Finally, gut microorganisms also metabolize mole-
cules that are secreted by the host into the gastroin-
testinal (GI) lumen. Primary bile acids, such as
glycocholic and taurochenodeoxycholic acid, are
released into the duodenum from the gall bladder to
facilitate the absorption of dietary lipids and lipophilic
vitamins. In the small intestine and, predominantly, in
the colon they are converted to secondary bile acids
(such as deoxycholic and lithocholic acids) by the
local microbiota (Fig. 1). This involves multiple steps,
with the initial deconjugation of glycine or taurine,
followed by dehydroxylation [76]. The enzymes
involved in these unique microbial modifications are
encoded by the gut microbiome, thus the bile acids
profile excreted in faeces, mainly composed by sec-
ondary bile acids, largely depends on the gut micro-
biota composition [77]. On the other hand, without
the microbial contribution, the host bile acid signature
is perturbed resulting in several GI, metabolic and
inflammatory disorders [78,79]. Primary and secondary
bile acids function as signalling molecules for various
cells of the immune system through interaction with
host bile receptors, such as ligand-activated nuclear
receptors such as the farnesoid-X-receptor (FXR) and
the vitamin D receptor, as well as the membrane-
bound G protein-coupled bile acid receptor (TGR5).
Importantly, these receptors are ubiquitously dis-
tributed in several tissues and have different affinity
for individual bile acids. For instance, TGR5 recog-
nizes both conjugated and free secondary bile acids
[80], whereas the primary bile acid chenodeoxycholic
acid is the most potent ligand for FXR [81]. The con-
sequence is that different microbial communities can
differentially affect bile signalling and determine the
degree of activation of these receptors with a con-
comitant impact on host metabolism. Interacting with
their receptors, they reduce the expression of proin-
flammatory cytokines from monocytes, macrophages,
dendritic cells (DCs) and hepatic macrophages known
as Kupffer cells [82]. Furthermore, it has been demon-
strated that free taurine itself can enhance the activa-
tion of the NLRP6 inflammasome, thereby increasing
the production of IL-18 by the intestinal epithelium,
which supports epithelial barrier function and mainte-
nance [83]. This novel gut microbiota-bile acid-host
signalling triangle represents the starting point for
microbiota-based therapeutic approaches to manage
diseases linked to alteration of bile acids metabolism.
Indeed, a cholesterol-lowering effect was observed
after administration of a Lactobacillus strain to mice
[84] as well as to hypercholesterolaemic subjects [85],
whereas administration of epigallocatechin-3-gallate




Several bacterial species, that is Lactobacillus and Bifi-
dobacterium species, have been used to improve human
health. The concept of probiotics evolved from a the-
ory first proposed by Nobel Prize laureate Eli Metch-
nikoff, who suggested in 1908 that the long life of
Bulgarian peasants depended on their consumption of
fermented milk products [87]. Organizations and agen-
cies such as Codex (which comes under the FAO/
WHO umbrella), Health Canada, the World Gastroen-
terology Organisation, the European Food Safety
Authority (EFSA) and the Institute of Food Technolo-
gists use the following definition when referring to pro-
biotics: ‘live microorganisms that, when administered
in adequate amounts, confer a health benefit on the
host.’ This definition describes the philosophy behind
the term ‘probiotics,’ that is microbial, viable and
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beneficial to health [88,89]. The beneficial effects of
probiotics have been demonstrated in diarrhoea, aller-
gies, inflammatory bowel disease, lactose malabsorp-
tion and NEC [90].
Prebiotics
The term ‘prebiotic’ was introduced in the 1980s and
refers to ‘non-digestible food ingredients that benefi-
cially influence the host by selectively stimulating the
growth and/or the activity of one or a limited number
of bacteria in the colon, thus improving host health’
[91]. SCFAs, peptidoglycans, polysaccharide A (PSA)
and various oligosaccharides belong to the prebiotics
family. Their main effect is on microbial metabolism,
and SCFAs are the most studied. Indeed, if dietary
fibres are present in the colon, the anaerobic bacteria
extract energy from the fermentation of the carbohy-
drate component, producing SCFAs, which are not
toxic to the host. Besides being an energy source,
SCFAs have various important physiological functions
including maintaining the luminal pH, inhibiting
pathogens’ growth, influencing bowel motility and
potentially reducing colon cancer by causing cancer
cell apoptosis [89]. Moreover, inulin, galacto-oligosac-
charides (GOS), fructo-oligosaccharides, soybean
oligosaccharides and xylo-oligosaccharides are the
oligosaccharides considered prebiotics [92]. GOS and
short-chain trisaccharides (such as sialyllactose or
fucosyllactose) present in human milk are usually the
first prebiotics used by humans to promote the growth
and the activity of Bifidobacterium and Lactobaccillus
species in infants [93]. Prebiotics act as regulatory fac-
tors of the immune system due to their ability to
directly stimulate toll-like receptors (TLRs) on intesti-
nal epithelial cells (IEC) and host immune cells induc-
ing the expression of anti-inflammatory cytokines (i.e.
IL-10 and TGFb). In addition, SCFAs and other bac-
terial metabolites might stimulate the expression of G
protein-coupled receptors, such as Gpr41 and Gpr43,
on the IEC to limit host inflammatory responses
[90,94].
Ten years ago, Gibson introduced the concept of
synbiotics, a combination of prebiotics and probiotics
meant to strengthen the effects of probiotics adminis-
tered alone [95]. Synbiotics are used to improve sur-
vival of live microbial dietary supplements in the GI
tract and to selectively stimulate the growth and/or
activate the metabolism of health-promoting bacteria
[96].
In summary, while the effectiveness of these agents
seems promising, additional studies are needed to
establish recommendations for most clinical settings.
Faecal microbial transplantation
In addition, faecal microbial transplantation (FMT)
from healthy donors into the bowel of patients suffer-
ing from recurrent diarrhoea due to the antibiotic-re-
sistant Clostridium difficile has emerged as an
alternative option to treat severe cases of C. difficile
infections [97]. The efficacy rate for these patients is
about 90%, dramatically higher than with antibiotic
therapies [98]. Based on these data, FMT is now
included in the standard practice for treating recurrent
and refractory C. difficile infections, the only indica-
tion approved by the Food and Drug Administration
(FDA) since 2013 (FDA-2013-D-0811-0022) [99]. The
mechanisms underlying probiotics function have been
the object of intensive investigation and include the
following: (a) increased integrity and enhancement of
the epithelial barrier; (b) increased adhesion to the
intestinal mucosa and concomitant inhibition of patho-
gen adhesion; (c) competitive elimination of pathogens;
(d) production of antimicrobial substances; (e) modu-
lation of DCs; (f) effect on T-cell polarity; and (g)
modulation of the immune system and the inflamma-
tory response [90]. Even though probiotics have an
excellent overall safety record, for selected groups of
patients, particularly those with severe immunodefi-
ciency, malnutrition, cancer or preterm neonates, cau-
tion has to be taken. Indeed, bacteraemia, sepsis and
cholangitis induced by Bacillus subtilis or fungal sepsis
caused by Saccharomyces boulardii have been reported
[100].
Gut microbiota and human disease
Cardiovascular disease
In 2011, the American Heart Association committed
that by 2020 the cardiovascular status of Americans
should improve by 20%, aiming at reducing by the
same magnitude the deaths from CVD and stroke.
These goals became the foundation of the ‘Health
Campaign for Life’s Simple 7’ where ‘ideal cardiovas-
cular health’ is described by the lack of clinically mani-
fest CVD combined with optimal indexes for seven
major metrics, including (a) not smoking, (b) healthy
diet, (c) daily physical activity, (d) body weight, (e)
total cholesterol (TC), (f) blood pressure (BP) and (g)
fasting blood glucose, in the absence of any drug treat-
ment [101–103].
A recent meta-analysis of 12 878 individuals pro-
vided data on the importance of cardiovascular health
metrics on risk for clinical events. This meta-analysis
indeed inversely correlated the cardiovascular health
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metrics and the risk of stroke, CVD, cardiovascular
mortality and all-cause mortality [103,104]. Up to
now, about 92.1 million adults in the United States
have at least one type of CVD, and by 2030, 43.9% of
the US adult population is predicted to have some
form of CVD [105]. Moreover, the direct costs (cost of
physicians, hospital services, prescribed medications
and home health care) and indirect costs (loss of pro-
ductivity) of CVD and stroke in the United States
were $316.1 billion in 2013, and by 2030, it is pro-
jected to increase to $918 billion [103,106]. It is impor-
tant to note that 80% of CVD deaths take place in
low- and middle-income countries and occurs almost
equally in males and females. Indeed, a survey com-
paring the availability of aspirin, b-blockers, angioten-
sin-converting enzyme inhibitors and statins in 18
countries showed that these medications were poten-
tially unaffordable for 60% and 30% of households in
low- and in middle-income countries, respectively,
compared with only 0.14% of households in high-in-
come countries [107–109]. This dramatic scenario
appears to be dependent on the fact that, with greater
industrialization, Western-type diets instead of tradi-
tional plant-rich diets have become the most con-
sumed. As a consequence, a significant increase in
human pathologies such as obesity and type-2 diabetes
has been recorded [110]. These metabolic diseases are
now considered as a chronic low-grade inflammatory
disease, but the underlying mechanisms have not been
clearly elucidated [111,112].
Studies show that dietary habits influence various
‘old’ cardiovascular risk factors, including BP, TC,
glucose levels and obesity/weight gain, as well as ‘nov-
el’ risk factors, that is inflammation, cardiac arrhyth-
mias, endothelial cell function, triglyceride levels,
lipoprotein[a] levels and heart rate [113–115]. A clinical
study demonstrated that greater adherence to a
Mediterranean diet characterized by higher intakes of
vegetables, legumes, fruits, whole grains, fish and
lower intakes of red meat was associated with a 22%
reduction in cardiovascular mortality (RR, 0.78; 95%
CI, 0.69–0.87) [116–118]. These findings were con-
firmed by a randomized secondary prevention trial
enrolling patients with recent MI and by the PRE-
DIMED trial [103,119]. This latter clinical study
demonstrated a 30% reduction in the risk of stroke,
MI and death due to cardiovascular causes in those
patients randomized to Mediterranean-style diets rich
in extravirgin olive oil or mixed nuts [119].
Numerous studies have shown that atherosclerosis,
the dominant cause of CVD, is influenced by the
immune system with cytokines involved in all stages of
the disease [120–122]. Specifically, chronic inflammation
triggers the migration and proliferation of monocyte-
derived macrophages and T lymphocytes within the
plaques. It has been demonstrated that human
atherosclerotic plaques are characterized by a predomi-
nance of T helper (Th) cells secreting Th1 cytokines,
that is IFN-c and TNF-a, and few clones producing
Th2 cytokines. This Th1 milieu may contribute to the
thrombogenicity of the lesions by increasing the tissue
factor production, which associates with platelet acti-
vation and endothelial dysfunction [123]. The Canaki-
numab Antiinflammatory Thrombosis Outcomes Study
(CANTOS) trial demonstrated that anti-inflammatory
therapy targeting the IL-1b pathway markedly reduced
plasma levels of IL-6 and of C-reactive protein [124],
lowering the rate of recurrent cardiovascular events
compared with placebo, independently of lipid-level
lowering [125].
Several evidences suggested that the gut microbiota
regulates inflammation by affecting cytokine produc-
tion and haematopoiesis, as well as by affecting the
differentiation of inflammatory cell types [32,126,127].
An increase in lipopolysaccharide (LPS) plasma levels,
likely derived from gut bacteria [6,128], has been asso-
ciated with inflammatory cell infiltration in adipose tis-
sues, liver and pancreatic islets. LPS is a major
component of the outer membrane in Gram-negative
bacteria and its plasma levels are correlated with
changes in intestinal microbiota where the Gram-nega-
tive-to-Gram-positive ratio is increased by high-fat
feeding [129]. Besides, atherosclerotic plaques contain
bacterial DNA, and the bacterial taxa observed in
atherosclerotic lesions are also present in the gut of
the same individuals. This indicates that the gut micro-
biota could be a source of bacteria in the plaque,
which may affect plaque stability and the incidence of
CVD. In line with this hypothesis, a link between the
gut microbiota and the severity of MI has been
reported in an experimental model [130]. Also, the
high blood concentration of the microbiota-dependent
metabolite TMAO has been linked to an increased risk
of atherosclerosis, indicating a pivotal role for the gut
microbiota in atherogenesis (Fig. 1) [66]. In addition,
germ-free Apoe-deficient mice showed lower circulating
LPS levels, reduced systemic inflammation and
decreased atherogenesis compared with conventionally
raised Apoe-deficient animals [131,132]. Together, these
findings suggest a link between gut microbiota, host
immunity and atherogenesis (Fig. 2). This is supported
by a recent study by Brandsma et al. showing that
proinflammatory microbiota accelerated atherosclerosis
development in LDLr-deficient mice fed a high-fat/
high-cholesterol diet. Mice were also characterized by
increased proinflammatory plasma cytokines, and
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circulating and in-plaque monocytes and neutrophils,
as well as reduced levels of SCFAs in the caecum and
of SCFA-producing taxa [133,134].
The bacterium Akkermansia muciniphila, the most
abundant species in the human intestinal microbiota,
has been associated with anti-inflammatory functions.
Indeed, in genetically and diet-induced diabetic mice,
the levels of A. muciniphila were inversely correlated
with body mass, inflammation index, insulin resistance
and glucose tolerance [135]. Prebiotic feeding markedly
increased the abundance of A. muciniphila and reduced
fat mass, insulin resistance and liver steatosis. In line
with these results, the administration of A. muciniphila
protects against the development of atherosclerosis in
Apoe-deficient mice [72,136]. Also, metformin-treated
diabetic patients reported beneficial effects on
metabolic parameters linked to CVD risk [137]. It is
possible that the beneficial action of A. muciniphila is
due to the protein Amuc_1100, localized on the mem-
brane of the bacteria, which has been shown to play
immuno-modulatory roles both in vitro and in vivo
[138].
A leaky gut and alterations in gut microbiota com-
position can lead to the transfer of endotoxins into the
circulation promoting systemic inflammation and
development of obesity and related metabolic disease
[139]. Backhed et al. demonstrated that germ-free ani-
mals are protected from diet-induced obesity by two
main mechanisms that result in increased fatty acid
metabolism: (a) elevated levels of the fasting-induced
adipose factor, also called angiopoietin-like protein 4
(Angptl4), in the intestinal epithelium and (b)
Fig. 2. Major mechanisms involved in the cross-talk between microbes and host. The balance between healthy and pathological conditions
depends on different factors, including genes, food (Mediterranean vs. Western diet), prebiotic/probiotic intake, stress and antibiotic
treatments.
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increased AMP-activated protein kinase activity [140].
These data were not confirmed by Fleissner et al.
[141]. A recent study showed higher expression of the
Angptl4 gene in the small intestine of germ-free mice
compared with conventionally raised animals. Angptl4
expression was decreased upon gut recolonization
[142]. These conflicting data warrant further investiga-
tions into the role of Angptl4 in the intestinal epithe-
lium. Various clinical studies indicate that gut
microbiota play a key role in adiposity and glucose
metabolism, demonstrating that subjects with obesity
and type 2 diabetes have an altered microbiota compo-
sition [143]. Additionally, FMT from obese mice to
recipient germ-free mice significantly increased body
fat content and insulin resistance, compared to those
receiving FMT from lean mice [144]. Based on these
experimental results, several studies have evaluated the
possibility of altering the gut microbiome, that is by
FMT, as a potential therapy for obesity and the meta-
bolic syndrome [99]. In a small clinical study,
improved peripheral insulin sensitivity was associated
with increased levels of butyrate-producing intestinal
microbiota 6 weeks after FMT from lean donors into
patients with metabolic syndrome [145].
Mouse and human gut bacterial species are com-
posed for the most part (about 90%) of Bacteroidetes
and Firmicutes phyla. Homozygous genetically obese
(ob/ob) mice, carriers of a single autosomal recessive
mutation on the leptin encoding gene (also known as
the obese gene), are lacking functional leptin despite
showing high levels of leptin mRNA in adipocytes
[146]. Compared to their lean counterparts, ob/ob mice
have early-onset obesity, decreased abundance of Bac-
teroidetes and increased presence of Firmicutes [147].
Enrichment of hydrogen-oxidizing methanogens has
been observed in obese compared to normal weight
individuals. These microorganisms are critical for fer-
mentation since hydrogen accumulation in the colon
inhibits fermentation. Many of the hydrogen-oxidizing
methanogens detected in the human gut belong to the
Firmicutes phylum, and this may partly explain why
an increase in Firmicutes has been observed in obesity
[148].
Central nervous system disease
The ‘gut–brain axis,’ consisting of a series of inte-
grated physiological functions (neural, endocrine)
based on the bidirectional interaction of intestine and
CNS, is well established (Fig. 3) [149]. It has become
increasingly evident that, through various mechanisms,
gut microbiota are active elements of the gut–brain
axis. The CNS can influence the gut microbiota
through metabolic and endocrine pathways and via
the release of signalling molecules such as cytokines
and peptides [150]. On the other hand, the microbiota
can influence CNS function in several ways, including
the release of molecules that, once in circulation, can
Fig. 3. The gut–brain axis. Brain and gut
communicate bidirectionally. Stress
conditions trigger CNS responses that may
lead, chronically, to the development of
neuropsychiatric and neurodegenerative
disorders. This causes aberrant release of
soluble mediators, including cytokines and
neurotransmitters, which affect the
functionality of the gut and the gut
microbiota. On the other hand, microbiota
products produced by a dysbiotic intestinal
flora can cause gut permeability, leaking
bioactive molecules into circulation. As they
reach the brain, they can affect brain
function exacerbating CNS disease.
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reach the CNS and activate specific receptors on neu-
ral cells (Fig. 3). This bidirectional interaction between
microbiota and CNS occurs from development
through adult life. It is known, for example, that expo-
sure to early life stress is able to trigger disturbances
in the composition of the adult gut microbiota, and
this can be counteracted by probiotic administration
[151]. Stress-induced modifications in the gut micro-
biota composition have been shown in preclinical
models as well, where animals developing stress-in-
duced despair behaviour show alterations in micro-
biota composition and function, specifically in the
Lactobacillus genus. Reactive oxygen species produced
by Lactobacillus species negatively affect the metabo-
lism of kynurenine, a serotonin precursor, thus possi-
bly affecting brain function [152].
The stability of the gut microbiota has been asso-
ciated with neuropsychiatric diseases. It is worth
mentioning that also blood circulating microbiota
have been suggested to play a role in neuropsychi-
atric disorders [153]. In a study on major depressive
disorder, faecal samples from affected patients dis-
played increased Bacteroidetes, Proteobacteria and
Actinobacteria, whereas Firmicutes levels were signifi-
cantly reduced compared to age-matched controls,
and these alterations positively correlated with the
severity of depressive symptoms [154]. Furthermore,
FMT from depressed patients into germ-free mice
induced depressive- and anxiety-like behaviours, pos-
sibly through glucocorticoid signalling, thus correlat-
ing the gut microorganisms with the development of
depression [155]. Alterations in gut microbiota have
also been identified in patients with autism spectrum
disorder (ASD). It is well established that individuals
with ASD suffer from GI tract complications.
Though the cause is still unclear, this appears to be
related to abnormal gut flora and/or excessive use of
antibiotics that contribute to further alter the gut
microbiota [156,157]. ASD severity has been strongly
correlated with GI symptoms, as well as alterations
in the gut bacterial species Bifidobacter and Lacto-
bacillus [157]. Prebiotic intervention in ASD paedi-
atric patients lowers the abundance of
Bifidobacterium species and Veillonellaceae family
bacteria and concomitantly increases F. prausnitzii
and Bacteroides species levels. This regimen proves
to be beneficial, triggering changes in faecal metabo-
lites and improvements in GI symptoms as well as
in antisocial behaviours, one of the hallmarks of
ASD [158]. Recent studies highlighted that ASD
patients may also display alterations in the GI bacte-
rial phyla Bacteroidetes and Firmicutes, with higher
abundance of Sutterella, Odoribacter and
Butyricimonas, and lower abundance of Veillonella
and Streptococcus genera [159].
Evidence of altered gut microbiota in individuals
diagnosed with bipolar disorder has been found.
Patients show increased levels of Flavonifractor Bac-
terium, Actinobacteria and Coriobacteria phyla, which
may induce oxidative stress and inflammation in the
host, although other factors, such as smoking, may
also contribute to the dysbiosis [160].
Alterations in the gut microbiota have been reported
in Parkinson’s disease (PD), the most common move-
ment disorder [161]. Although motor dysfunction is
central in PD, nonmotor symptoms have received
growing attention in the last decade [162]. Gut dysbio-
sis has been associated with the severity of PD symp-
toms. Indeed, the abundance of Prevotellaceae in
faeces of PD patients was shown to be reduced by
77.6% compared with unaffected individuals, and the
relative abundance of Enterobacteriaceae was posi-
tively associated with the severity of postural instabil-
ity and gait difficulty [163]. Furthermore, GI disorders,
possibly associated with dysbiosis, are known to be
prominent and disabling in PD patients [164] and have
been suggested to precede the onset of motor symp-
toms by years [165]. Lewy bodies, a-synuclein aggre-
gates characteristic of PD neuropathology [166], are
also found in the GI system of PD patients both
undergoing treatment and newly diagnosed, thereby
never exposed to PD drugs [167]. This has prompted
intensive investigations into the profiling of the gut
microbiome in newly diagnosed PD patients, as it may
lead to the identification of reliable early biomarkers
that can allow precocious therapeutic intervention to
slow or stop the course of the disease [161].
Alzheimer’s disease (AD) is the primary cause of
dementia in the ageing population and is characterized
by the progressive decline of cognitive functions [168].
Neuropathological hallmarks of the AD brain are neu-
rofibrillary tangles of Tau protein aggregates, and pla-
ques of amyloid beta peptide [169]. It has been shown
that diet and specific nutrients can modify the compo-
sition of the gut microbiota influencing the production
and/or aggregation of amyloid proteins through mech-
anisms of molecular mimicry [170]. Computational
studies also associated cognitive decline in AD with
metabolites such as succinic acid, mannitol, 4-hydroxy-
benoic acid (DOPAC) and TMAO, the latter being a
gut microbial metabolite of dietary meat and fat
(Fig. 1) [171]. Clinical studies performed on cerebro-
spinal fluid samples have demonstrated that TMAO
may be relevant to the neurodegenerative changes in
AD-related tau pathology, thus confirming the role of
the gut–brain axis in the pathophysiology of AD [172].
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Comprehensive 16s rRNA sequencing of stool samples
of AD patients demonstrated their microbiome has
decreased microbial diversity, with an increased rela-
tive abundance of Lactobacillales, and decreased abun-
dance of Bacteroidales and Selenomonadales [173].
Multiple sclerosis (MS) is a chronic, inflammatory,
demyelinating disease of the CNS. Though its aetiol-
ogy is unknown, MS is initiated and sustained by the
synergistic contribution of dysregulated immunity,
genetic susceptibility and environmental factors. Hall-
marks of MS are white and grey matter demyelinating
lesions in the brain and spinal cord, where demyelina-
tion occurs through the concerted action of immune
cells (T cells, B cells, macrophages) infiltrating into the
CNS and CNS-resident cells, mostly microglia and
astrocytes [174]. Studies on the gut microbiota in MS
have provided evidence of alterations at the levels of
phyla and genera in MS patients, such as an increase
in Methanobrevibacter and Akkermansia and decrease
in Butyricimonas. Compared with untreated patients,
patients on treatment have increased abundance of
Prevotella and Sutterella [175]. Microbial dysbiosis was
also confirmed in another study on patients affected
by relapsing–remitting MS displaying increases in
Psuedomonas, Mycoplana, Haemophilus, Blautia and
Dorea genera [176]. Modifications of the gut micro-
biota have been detected in early-onset paediatric MS,
where patients showed enrichment in microorganisms
involved in glutathione metabolism, suggestive of a
proinflammatory environment [177]. Moderate dysbio-
sis was also reported in a study on a small cohort of
Japanese relapsing–remitting MS patients. In this
study, 20 patients were analysed (12 who were under
therapeutic regimen and eight that never received any
type of treatment) and compared to control individu-
als. Faecal samples were collected during the remission
phase. The mixed MS group exhibited alterations of
intestinal taxa comprised primarily of Clostridium spe-
cies belonging to Clostridium clusters XIVa and IV
and Bacteroidetes [178].
From a preclinical standpoint, various studies in the
experimental autoimmune encephalomyelitis (EAE)
model of MS have highlighted the role of the gut
microbiota in the development of motor symptoms.
Ochoa-Reparaz et al.[179] have shown that oral treat-
ment with antibiotics can induce the accumulation of
FoxP3+ Treg cells in distal peripheral lymph nodes
and reduce the severity of EAE. This indicates that
modifications of gut commensal bacteria can modulate
peripheral immune tolerance that ultimately confers
protection from EAE in mice. Studies from the same
group have underscored the protective role of PSA, a
nontoxic component of the human commensal
microbiota produced by Bacteroides fragilis. Oral
administration of purified PSA produced by B. fragilis
induced protection from EAE in mice, reducing its
severity [180]. In a large-scale screen of MS patients,
increases in A. muciniphila and Acinetobacter cal-
coaceticus taxa have been identified. These have been
shown to trigger proinflammatory responses and main-
tain the proinflammatory environment. Indeed, FMT
from MS patients into germ-free mice induced more
severe EAE symptoms compared to mice colonized
with microbiota from healthy age-matched controls.
This indicated a causal role for the gut microbiota in
MS development [181].
Cancer
Cancer is the second leading cause of death worldwide,
resulting from the random accumulation of sponta-
neous mutations during DNA replication, together
with environmental exposure and lifestyle habits, both
able to dramatically affect cancer risk [182–184]. In
recent years, accumulating evidence highlighted the
role of commensal bacteria as key determinants of
health or pathologic conditions, including cancer
[185,186]. Various experimental studies performed on
germ-free animals demonstrated that gut microorgan-
isms promote carcinogenesis in various organs such as
lungs, skin and breast [187], and there is an inverse
relationship between cancer development and intestinal
microbiota depletion by antibiotics [188]. In addition,
accumulating evidence indicated that dysbiosis is asso-
ciated not only with tumours arising in the affected
organs but also in distant organs [189,190]. The high
degree of variability on both the number of microor-
ganisms and their diversity in different organs and
from individual to individual could be responsible for
the above-described phenomenon [191].
The tumour microenvironment, where the neoplastic
and immune cells interact with microorganisms and
vice versa, is dramatically affected by genetic and epi-
demiological factors [192,193]. The communication
between the gut microbiota system and the body
organs is controlled by the intestinal permeability (IP).
Importantly, mechanisms regulating IP control the
exchange between the intestinal content and the portal
blood. Food, intact bacteria and bacterial components,
that is bacterial DNA, peptidoglycans (molecules
belonging to the class of pathogen-associated molecu-
lar patterns) can reach the liver in large amount
depending upon the degree of IP [194]. Indeed, IP
degree is highly variable and results from the combina-
tion of several factors: diet, gene expression, intestinal/
liver pathology, surface mucus, tight junction integrity
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and production of immunoglobulins [195]. The micro-
biota can contribute to carcinogenesis both by enhanc-
ing or diminishing the risk through three main
mechanisms: (a) altering the balance of cell prolifera-
tion and death; (b) modulating immune system func-
tion; and (c) affecting the metabolism of ingested
foods, host-produced factors and drugs. In addition, it
is important to remember that the host immune system
supports the gut microorganisms while protecting
against pathogenic microbes. In essence, human gut
microbiota carry out a pivotal role in cancer initiation,
development and its response to cancer therapy
(Fig. 4) [196].
Carcinogenic microorganisms include Helicobac-
ter pylori and Epstein–Barr virus for gastric carcinoma
[197]; hepatitis B and C viruses for hepatocellular car-
cinoma [198]; human herpesvirus-8 for Kaposi’s sar-
coma [199]; human papilloma virus for uterine cervical
cancer [200]; and Fusobacterium nucleatum for colorec-
tal carcinoma (CRC) [201]. By quantitative PCR anal-
ysis, high prevalence of F. nucleatum sequences in
tumour vs. normal tissue was detected and correlated
with lymph node metastasis [202]. It has been hypothe-
sized that these F. nucleatum sequences promote car-
cinogenesis by stimulating the Wnt signalling cascade
in CRC [203,204]. The correlation between abdominal
infections and increased risk of CRC development
reinforces the clinical correlation between dysbiosis
and carcinogenesis. Alteration in the gut microbiota
community directly modulates the probability of devel-
oping CRC in genetic and mutagen-induced animal
models of carcinogenesis [205]. Experimental studies
performed in germ-free or cohoused mice, as well as in
gnotobiotic models and mice treated with antibiotics,
strengthen the role played by the intestinal microor-
ganisms in CRC and hepatocellular carcinoma
[206,207]. Dysbiosis in patients with CRC has been
detected in several studies [208,209]. Besides, F. nuclea-
tum could be also regarded as a marker of CRC sus-
ceptibility [210], being abundantly found in patients
suffering from chronic gut inflammation, that is
inflammatory bowel disease [211,212]. It has been
shown that the adhesion molecule FadA from F. nu-
cleatum attaches to E cadherin leading to activation of
b-catenin in CRC tumours, promoting inflammation
and tumour development [213]. Coherent with these
data, FadA is elevated in human CRC samples.
Besides their tumour-inducing actions, microbiota
have also been reported to display anticancer activities
[187]. For instance, TLRs and NOD-like receptors-
based treatments promote the antitumor effects of
microbiota, as the innate immune system could acti-
vate the anticancer responses [214,215]. Indeed, a
reduction of cell growth and cancer risk was demon-
strated in Trl-4-deficient mice and with FMT from
wild-type into Nod-2-deficient mice, respectively
[216,217]. Similarly, microbial-derived SCFAs are able
to inhibit host’s tumour cell histone deacetylase caus-
ing antitumour effects, as shown in both CRC and
lymphoma [218,219]. These data indicate that several
commensal bacteria could potentially be used for their
probiotic activity, that is protecting against gut dysbio-
sis and/or enhancing host immune defence mecha-
nisms, in combination therapies. One example is
Lactobacillus casei, which can trigger tumour apopto-
sis via JNK pathway activation on host’s immune
cells, that is NK cells and DCs, leading to the suppres-
sion of cancerous or precancerous cells [220,221]. Vari-
ous clinical investigations have been designed to
address the potential of single strain probiotics at
improving antitumour immune response [222,223].
Probiotics or synthetic stools have sought to recapitu-
late the benefits of FMT in delivering a diverse ecosys-
tem in a product easy to manufacture and with
Fig. 4. Interactions between gut microbiota
and cancer therapies. Chemotherapeutic
agents can undergo metabolic inactivation
by bacterial present in the GI tract (gut
microbiota) or within the tumour
(intratumour microbiota). As an alternative,
gut microbiota can reactivate the drugs
leading to treatment-related systemic
toxicity. On the other hand, cancer therapy
can exert a bacteriostatic effect on the gut
microbiota causing dysbiosis.
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minimal lot-to-lot variation (i.e. consistent composi-
tion). Preliminary results obtained with these products
in recurrent C. difficile infections demonstrated stable
engraftment of a diverse microbial community [224].
Many foods or food components have been associated
with increase or decrease in the risk of cancer. Nowa-
days, the idea is that different dietary ingredients work
together to generate a meta-inflammatory milieu
responsible or not of tumour progression. Neverthe-
less, whether specific dietary components might
favourably alter the microbiota is still an open ques-
tion. Data from short-term dietary studies showed that
a dramatic shift in diet could equally impact on the
microbiota as well as on cancer biomarkers, that is cel-
lular proliferation [225–227].
Cancer therapy
Data from preclinical and human studies have coher-
ently indicated that both the tumour microenviron-
ment and the gut microbiota may influence therapeutic
efficacy and tolerability of anticancer therapy by
affecting microbial diversity and the abundance of
specific taxa (Fig. 4) [228–230].
Specifically, microbial beta-glucuronidase (GUS)
enzymes have been linked to the GI side effects of
drugs, tumour progression and increased incidence of
Cohn’s disease and colitis [231]. GUS enzymes play a
key role in the metabolic fate of molecules important
in host health and disease, including bilirubin, hor-
mones, neurotransmitters, bile acids, fatty acids and
many anticancer agents. Indeed, bacterial GUS
enzymes regenerate the original drug inactivated by
the host, increasing its half-life and sometimes its toxi-
city. For this reason, 89% of glucuronated-chemother-
apic drugs exhibit GI toxicity that is mediated, at least
in part, by bacterial GUS activity, resulting in a para-
sitic symbiosis in which bacteria receive sugar from
drug glucuronides and the host retains toxic metabo-
lites [232]. For example, SN-38, the active form of
irinotecan, which is used to treat colorectal and pan-
creatic cancers, is inactivated in the liver by conversion
into SN-38-glucuronide [232]. In the gut, microbial
GUS enzymes recreate SN-38 and cause severe GI tox-
icity in the form of dose-dependent diarrhoea that is
reduced by the selective inhibition of GUS enzyme
activity [215].
Although insight has been gained on the role of the
gut microbiota in response to cancer therapy, more
studies are needed to fill significant gaps of knowledge
in the components of the human gut microbiota and
how they interact and influence one another and the
whole immune response.
Conclusion
The importance of the human gut microbiota in health
and disease has emerged over the past decade. Each
person’s microbiome is unique, rapidly developing
throughout early childhood and relatively stable but
susceptible to changes in adulthood. These variations
in microbial composition can be influenced by both
genetic and environmental factors, including diet, geo-
graphical location, toxin/carcinogen exposure and hor-
mones. Dysbiosis, meaning imbalances in the
composition and function of the intestinal microbes, is
associated with various human diseases. Despite cur-
rent unresolved questions that limit interpretative and
translational capabilities, the possibility of correcting
gut dysbiosis by microbiota-based interventions repre-
sents an intriguing approach in preventing and treating
human pathologies.
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